drugset / Trial / NCT04093531
Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This pilot study will make a preliminary determination of the safety of ustekinumab in patients with Primary Sjogren's Syndrome (PSS) and assess the response of systemic measures of inflammation (biomarkers).
Timeline
- Start
- 2020-01-15
- Primary completion
- 2022-05-11
- Completion
- 2022-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ustekinumab | Monoclonal antibody | 90 mg | Intravenous |